Study of BGB-A317 in Patients With Previously Treated Unresectable HCC



Status:Recruiting
Conditions:Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/22/2018
Start Date:April 9, 2018
End Date:September 2021
Contact:Jeannie Hou, Senior Director
Email:clinicaltrials@beigene.com
Phone:1 (877) 828-5568

Use our guide to learn which trials are right for you!

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

This is a Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and
Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously
Treated Hepatocellular Unresectable Carcinoma.


Inclusion Criteria:

1. Histologically confirmed HCC

2. Patients with Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC stage B not
amenable to locoregional therapy or relapsed after locoregional therapy, and not
amenable to a curative treatment approach

3. Has received at least 1 line of systemic therapy for unresectable HCC

4. Has at least 1 measurable lesion as defined per RECIST v1.1

5. Child-Pugh score A

6. Easter Cooperative Oncology Group (ECOG) Performance Status ≤ 1

7. Adequate organ function

Exclusion Criteria:

1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
histology

2. Prior therapies targeting PD-1 or PD-L1

3. Has Known brain or leptomeningeal metastasis

4. Tumor thrombus involving main trunk of portal vein or inferior vena cava

5. Loco-regional therapy to the liver within 4 weeks before enrollment

6. Medical history of interstitial lung disease, non-infectious pneumonitis or
uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis,
acute lung diseases, etc

7. Has received:

1. Within 28 days or 5 half-lives (whichever is shorter) of the first study drug
administration: any chemotherapy, immunotherapy (eg, interleukin, interferon,
thymoxin) or any investigational therapies

2. Within 14 days of the first study drug administration: sorafenib, regorafenib, or
any Chinese herbal medicine or Chinese patent medicines used to control cancer

8. Active autoimmune diseases or history of autoimmune diseases that may relapse

9. Patient with any condition requiring systemic treatment with either corticosteroids (>
10 mg daily of prednisone or equivalent) or other immunosuppressive medication within
14 days before study drug administration
We found this trial at
6
sites
Newark, New Jersey 07103
Principal Investigator: Nikolaos Pyrsopoulos
Phone: 973-972-5252
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Hefei, Anhui 23060
Principal Investigator: Yueyin Pan
?
mi
from
Hefei,
Click here to add this to my saved trials
460 West 10th Avenue
Kettering, Ohio 45409
Principal Investigator: Charles Bane
?
mi
from
Kettering, OH
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Ghassan Abou-Alfa
Phone: 646-888-4184
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Benjamin Tan
Phone: 314-362-9115
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
White Plains, New York 10601
Principal Investigator: Dan Costin
Phone: 914-849-7582
?
mi
from
White Plains, NY
Click here to add this to my saved trials